{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363386073374426496.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.dmpk.2018.08.006"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1347436718300508?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S1347436718300508?httpAccept=text/plain"}},{"identifier":{"@type":"NAID","@value":"210000173400"}}],"dc:title":[{"@value":"Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420282801194398464","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"10789580"},{"@type":"NRID","@value":"1000010789580"},{"@type":"NRID","@value":"9000415184005"},{"@type":"NRID","@value":"9000415180538"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/Hkn"}],"foaf:name":[{"@value":"Keiko Hikino"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326221829632","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"50506722"},{"@type":"NRID","@value":"1000050506722"},{"@type":"NRID","@value":"9000258292935"},{"@type":"NRID","@value":"9000413358924"},{"@type":"NRID","@value":"9000415184006"},{"@type":"NRID","@value":"9000415198573"},{"@type":"NRID","@value":"9000010479077"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/8191"}],"foaf:name":[{"@value":"Koya Fukunaga"}]},{"@id":"https://cir.nii.ac.jp/crid/1581417282975446400","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000415184007"}],"foaf:name":[{"@value":"Taisei Mushiroda"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13474367"}],"prism:publicationName":[{"@value":"Drug Metabolism and Pharmacokinetics"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2018-12","prism:volume":"33","prism:number":"6","prism:startingPage":"243","prism:endingPage":"249"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S1347436718300508?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S1347436718300508?httpAccept=text/plain"}],"createdAt":"2018-09-01","modifiedAt":"2025-10-22","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360292619058965376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<i>CYP2C19</i>\n                    Pharmacogenomics Associated with Therapy of\n                    <i>Helicobacter Pylori</i>\n                    Infection And Gastro-Esophageal Reflux Diseases With A Proton Pump Inhibitor"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621364851200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Insurance Coverage Policies for Personalized Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569515728640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570563310720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043817890816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Stakeholder Views on Pharmacogenomic Testing"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520185592448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521159588864","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995458406144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943876591744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945917645312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946118510848","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420533007360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544421024870912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Trends and Outcomes of Malignant Hyperthermia in the United States, 2000 to 2005"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369499165568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Personalized medicine: Factors influencing reimbursement"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843951755264","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844351836800","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical and economic challenges facing pharmacogenomics"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845009945088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pharmacogenetics: From Bench to Byte— An Update of Guidelines"}]},{"@id":"https://cir.nii.ac.jp/crid/1373386073374426502","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina"}]},{"@id":"https://cir.nii.ac.jp/crid/1373386073374426507","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1373386073374426510","@type":"Product","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205105114752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Impact of Cytochrome P450 2C19*2 Polymorphism on Intra-Stent Thrombus After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680081053568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of Cytochrome P450 2C19 Polymorphism on Target Lesion Outcome After Drug-Eluting Stent Implantation in Japanese Patients Receiving Clopidogrel"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.dmpk.2018.08.006"},{"@type":"CIA","@value":"210000173400"}]}